JAK Inhibitors Lead Ulcerative Colitis Remission Rates

A single-center retrospective cohort study compared steroid-free remission outcomes across three biologic and small-molecule treatment classes.

Updated on Nov. 2, 2026 in Employment

JAK Inhibitors Lead Ulcerative Colitis Remission Rates

A retrospective cohort study of 390 ulcerative colitis patients treated between 2020 and 2025 found that JAK inhibitors were associated with higher 52-week steroid-free clinical remission than TNF inhibitors (RR = 1.68; P < 0.001). The findings were presented at the ACG Annual Scientific Meeting in Nashville, Tenn., on Oct. 12-14, 2026.

Why it matters

The study examines how these therapies perform in routine clinical care rather than only in controlled trials, which can inform treatment decisions for patients with ulcerative colitis. Its propensity score-weighted design uses real-world patient data, though its retrospective, single-center nature limits how far the results can be generalized.

The single-center retrospective cohort enrolled 390 patients, with JAK inhibitor recipients showing a steroid-free remission rate 1.68 times that of TNF inhibitor recipients (P < 0.001) and complete mucosal healing 1.58 times higher. Because JAK inhibitor patients began with greater disease severity and prior biologic exposure, and the vedolizumab advantage was not significant (P = 0.074), treatment-selection bias remains an open question.

The players

American College of Gastroenterology (ACG)

The American College of Gastroenterology is a professional medical society that hosts an annual scientific meeting for gastroenterologists and researchers.

Baylor Scott & White Medical Center

Baylor Scott & White Medical Center is a large multi-hospital health system in Texas and the single study site for this retrospective cohort analysis.

The details

Researchers tracked patients who initiated TNF inhibitors, vedolizumab, or JAK inhibitors from 2020 to 2025, measuring 52-week steroid-free clinical remission as the primary outcome. Secondary measures included treatment failure, hospitalization, steroid restart, emergency department visits, and endoscopic healing, with JAK inhibitors also linked to lower rates of several of these adverse outcomes.

2020 to 2025: Patients initiated TNF inhibitors, vedolizumab, or JAK inhibitors during the study period.
Oct. 12-14, 2026: Findings were presented at the ACG Annual Scientific Meeting.

Big Picture

This study builds on the real-world evidence that has accumulated since tofacitinib (Xeljanz) became the first JAK inhibitor approved for ulcerative colitis in 2017, offering comparative data against TNF inhibitors in routine practice. It adds to a growing body of observational research assessing whether JAK inhibitors' trial-based efficacy holds across broader patient populations.

Patients with ulcerative colitis whose disease has not responded to TNF inhibitors may find JAK inhibitors discussed as an option, though this study is observational and cannot establish causation. Any change in treatment should be weighed with a gastroenterologist, considering side effects and the patient's own clinical history.

The takeaway

Observational data suggest JAK inhibitors may outperform TNF inhibitors for steroid-free remission in ulcerative colitis, but treatment-selection bias means these findings should be confirmed in controlled trials before guiding individual decisions.